article thumbnail

Media Briefing on the Next Steps of the Rescheduling Process

Americans for Safe Access

For immediate release: Media Briefing on the Next Steps of the Rescheduling Process July 22, 2024, 1 pm ET Zoom Conference: Please go to the bottom of this page for the Zoom sign-in link.

Media 130
article thumbnail

The Truth About Smoking Marijuana and Lung Health

Cannabis Cheri

Even though the JAMA study got significant media attention, it is nothing new under the sun. It is interesting to note that in all the media stories about the JAMA article, there were a multitude of caveats and warning intoned by researchers not to consider cannabis safe just because they found it was.

Marijuana 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HHS Report on Cannabis Scheduling is Available & Statement from ASA

Americans for Safe Access

We are hopeful that the DEA will agree with HHS’ recommendation to change cannabis’ status and that Congress views HHS’ report as a greenlight to move forward with a more comprehensive approach to medical cannabis access.”

DEA 130
article thumbnail

A Proposed Social Media Drug Reporting Bill Raises Privacy Concerns

Veriheal

A disputable new social media drug reporting bill believes that social media companies should screen client posts and report any drug-related exercises to the DEA. Supporters of this social media drug reporting bill argue this will help crack down on dangerous drug trafficking happening online.

Media 52
article thumbnail

DEA Increases Access to Cannabis for Research Purposes

Veriheal

President of the Scottsdale Research Institute and prominent cannabis researcher Dr. Sue Sisley was quoted telling media, “there are thousands of different cannabis varieties that all have unique chemical profiles and produce unique clinical effects, but we didn’t have access to that normal diversity.”

DEA 66
article thumbnail

Press Release: Cybin Granted DEA Schedule I Manufacturing License

Cannabis Law Report

Cybin Granted DEA Schedule I Manufacturing License. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company’s research lab in the Boston area.

DEA 52
article thumbnail

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

Cannabis Law Report

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products. investor@curepharma.com.